Physician profile
Scott R Samuelson
NPI 1972555936
$3,828.59
in general payments reported to CMS, 2019-2025
31 companies · $841 in 2025
The $841 reported for 2025 was more than what 77% of Podiatrist providers received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $104 · 2020: $178 · 2021: $518 · 2022: $572 · 2023: $998 · 2024: $618 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,457.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $1,115.14 | 2019-2025 | Puraply Wound Matrix, Puraply, Affinity |
| Paratek Pharmaceuticals, INC. | $872.43 | 2021-2025 | Nuzyra |
| Treace Medical Concepts, INC. | $557.92 | 2020-2025 | |
| Smith+Nephew, INC. | $155.10 | 2019-2024 | Grafix Pl, Grafix, Oasis |
| Ossio INC | $131.07 | 2022 | |
| Convatec INC. | $115.68 | 2023-2024 | |
| Abbvie INC. | $114.31 | 2021-2024 | Dalvance |
| Nevro Corp. | $85.95 | 2023-2024 | Senza |
| Averitas Pharma INC. | $76.07 | 2023-2025 | Qutenza |
| Zimmer Biomet Holdings, INC. | $65.86 | 2021-2024 | Nextremity General Instrument, Tapestry, Stratum Foot Plating System |
| Next Science LLC | $57.21 | 2023-2025 | Blastx, Xperience, Surgx |
| Solventum Corporation | $43.34 | 2024-2025 | Activ.A.C., Promogran Prisma, V.A.C. Dermatac |
| Vertex Pharmaceuticals Incorporated | $42.06 | 2024-2025 | |
| Biotissue Holdings INC. | $33.21 | 2021 | |
| Kci USA, INC. | $33.11 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $32.63 | 2025 | Augment Injectable |
| Kerecis Limited | $31.95 | 2020-2021 | |
| Djo, LLC | $30.23 | 2021 | |
| Bioventus LLC | $27.29 | 2022 | |
| Reprise Biomedical, INC. | $24.22 | 2024 | Miro3d |
| Reddress USA, INC. | $23.22 | 2023 | |
| Sanara Medtech INC. | $19.04 | 2023 | Celleraterx |
| Melinta Therapeutics, LLC | $18.95 | 2019 | |
| Synergy Orthopedics, LLC | $17.32 | 2023 | |
| Nabriva Therapeutics, Plc | $16.79 | 2022 | |
| Grt US Holding, INC. | $16.55 | 2022 | |
| Depuy Synthes Sales INC. | $15.60 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $14.87 | 2023 | Seglentis |
| Paragon 28, INC. | $14.59 | 2024 | Portfolio |
| Horizon Therapeutics Plc | $13.82 | 2021 | |
| Wright Medical Technology, INC. | $13.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Samuelson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.